Research programme: dysferlin gene therapies - Genethon

Drug Profile

Research programme: dysferlin gene therapies - Genethon

Alternative Names: AAV1 dysferlin gene therapy - Genethon; Adenoviral-associated vector-mediated dysferlin gene therapy - Genethon; Dystrophy-associated fer-1-like protein therapy - Genethon; Gene therapy for dysferlinopathies - Genethon; Girdle muscular dystrophy 2B gene therapy - Genethon; Miyoshi myopathy gene therapy - Genethon

Latest Information Update: 25 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genethon
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Muscular dystrophies

Most Recent Events

  • 25 Feb 2016 Preclinical development is ongoing in France
  • 17 Jul 2013 Preclinical development is ongoing in France
  • 01 Aug 2011 Preclinical development for Muscular dystrophies (dysferlinopathies) is ongoing in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top